Viridian Therapeutics
VRDN
44 hedge funds and large institutions have $46.1M invested in Viridian Therapeutics in 2017 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 2 closing their positions.
650% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 2
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
42% more funds holding
Funds holding: 31 → 44 (+13)
0.19% more ownership
Funds ownership: 1.38% → 1.57% (+0.19%)
20% less capital invested
Capital invested by funds: $57.4M → $46.1M (-$11.3M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$3.58M |
| 2 |
AG
Artal Group
Luxembourg
|
+$1.12M |
| 3 |
BW
Biegel & Waller
Columbia,
Maryland
|
+$746K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$601K |
| 5 |
BlackRock
New York
|
+$374K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$1.58M |
| 2 |
Citigroup
New York
|
-$302K |
| 3 |
Barclays
London,
United Kingdom
|
-$41K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$35.2K |
| 5 |
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
|
-$31.5K |
VRDN Hedge Fund Activity: Q3 2017 in Review
44 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q3 2017, worth a combined $46.1M — down 20% from $57.4M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new VRDN positions and 2 closed out — a net gain of 13 holders — while 14 added to existing stakes and 8 trimmed.
The largest buyer was JP Morgan Chase, opening a new position worth an estimated $3.58M. The largest seller was Goldman Sachs, exiting entirely with an estimated $1.58M sold.
- 44 institutional investors held Viridian Therapeutics (VRDN) as of Q3 2017, up from 31 in Q2 2017.
- Funds reported $46.1M of Viridian Therapeutics stock for Q3 2017, down 20% quarter-over-quarter.
- 15 funds opened new Viridian Therapeutics positions in Q3 2017 and 2 closed out, a net change of +13 holders.
- The largest Viridian Therapeutics buyer in Q3 2017 was JP Morgan Chase, an estimated $3.58M added.
- The largest Viridian Therapeutics seller in Q3 2017 was Goldman Sachs, an estimated $1.58M sold.
Based on aggregated 13F filings for Q3 2017.